Document Detail

Serum tumor necrosis factor for monitoring response of hepatic veno-occlusive disease to pentoxiphyllin--a case report.
MedLine Citation:
PMID:  9246154     Owner:  NLM     Status:  MEDLINE    
Hepatic veno-occlusive disease (VOD) is the second most common cause of death after autologous bone marrow transplantation (ABMT). A patient with multiple myeloma undergoing ABMT developed classic features of hepatic VOD. He responded to treatment with pentoxiphyllin. Serum tumor necrosis factor (TNF) levels showed remarkable correlation with the severity of VOD and response to therapy.
P M Parikh; S H Advani; J S Nadkarni; S Kulkarni; G Kapoor; P S Sastry; M Anand; T K Saikia; R Gopal
Related Documents :
21271394 - Assessing the psychological well-being of caregivers of people living with hiv/aids in ...
21128884 - Hiv-1 (co)receptors: implications for vaccine and therapy design.
14586904 - Treatment of hepatitis c virus infection in the allograft.
21329724 - Neurological complications of hiv infection in critically ill patients: clinical featur...
23468504 - Adeno-associated virus-mediated gene transfer leads to persistent hepatitis b virus rep...
22558134 - Integrating prevention of mother-to-child hiv transmission programs to improve uptake: ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cancer investigation     Volume:  15     ISSN:  0735-7907     ISO Abbreviation:  Cancer Invest.     Publication Date:  1997  
Date Detail:
Created Date:  1997-08-25     Completed Date:  1997-08-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  326-8     Citation Subset:  IM    
Department of Medical Oncology, Tata Memorial Hospital Parel, Mumbai, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Transplantation / adverse effects
Dopamine / therapeutic use
Hepatic Veno-Occlusive Disease / blood*,  drug therapy*,  etiology
Multiple Myeloma / surgery
Pentoxifylline / therapeutic use*
Spironolactone / therapeutic use
Tumor Necrosis Factor-alpha / analysis*
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Tumor Necrosis Factor-alpha; 0/Vasodilator Agents; 52-01-7/Spironolactone; 6493-05-6/Pentoxifylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase II trial of topotecan in malignant melanoma.
Next Document:  The biological therapy of acute and chronic leukemia.